恩替卡韦联合逍遥散对肝纤维化肿瘤坏死因子TNF-α的影响  

The effect of entecavir combined with xiaoyao powder on tumor necrosis factor TNF- α with hepatic fibrosis in rat

作　　者：王庆生[1] 李绍民[1] 冯澜[1] 

机构地区：[1]佳木斯大学附属第一医院传染病科,黑龙江佳木斯154003

出　　处：《黑龙江医药科学》2016年第1期84-86,共3页Heilongjiang Medicine and Pharmacy

摘　　要：目的:采用硫代乙酰胺(TAA)诱导的大鼠肝纤维化模型进行实验研究,观察恩替卡韦联合逍遥散抗肝纤维化作用,对该方抗肝纤维化的可能作用机理进行研究。方法:SD雄性大鼠30只,随机分为肝纤维化模型组、恩替卡韦治疗组和恩替卡韦联合逍遥散治疗组。为大鼠皮下注射TAA,每周注射2次,连续注射至第6周,形成肝纤维化。药物治疗组于造模第7周开始,每天给予逍遥散水煎液8g/kg灌胃,每周恩替卡韦0.5mg/kg灌胃,6周后用腹腔注射麻醉大鼠后从眼球静脉丛取血收集血清。对模型组和治疗组的生化指标ALT和AST进行检测,利用放免试剂盒进行酶联免疫吸附试验(ELISA法)检测血清中TNF-α。结果:与模型组相比,治疗组显著降低了血清AST/ALT的活性,TNF-α浓度有明显降低。结论:恩替卡韦联合逍遥散可有效抑制促肝纤维化细胞因子TNF-α的表达,其机制可能与恩替卡韦联合逍遥散阻断纤维化形成过程中细胞因子的网络传递有关。Objective： To investigate the antifibrotic effect of entecavir combined with Xiaoyao power on thioacetamide（ TAA）- induced rat hepatic fibrosis. Methods： The 30 rats were randomly divided into three groups：nomal control group,model group and treated group. Thioacetamide（ TAA）（ 300 mg / kg body weight） was injected intraperitoneally 2 times a week into model group and treated group for 6 weeks to form liver fibrosis. Group3 were treated with entecavir（ 0. 5mg / kg） combined with Xiaoyao power（ 8g / kg） by gastric perfusion for six weeks.The changes of plasma biochemistry and TNF- α were measured with the methods of biochemistry and ELISA. Results： The treatment with entecavir combined with Xiaoyao power restored the biochemical parameters（ ALT / AST）towards normal. The level of TNF- α was significantly lower in the treated group compared to the model group.Conclusion： Entecavir was combined with Xiaoyao powder which can effectively inhibit the expression of hepatic fibrosis- promoting cytokines TNF- α. Entecavir combined with Xiaoyao may be block the network transmission of cytokines in the formation of fibrosis.

关 键 词：恩替卡韦联合逍遥散 肝纤维化 肿瘤坏死因子TNF-Α 硫代乙酰胺 

分 类 号：R575.2[医药卫生—消化系统]